Peer-reviewed veterinary case report
Lomustine treatment results for cats with GI lymphoma
By Rau, S E & Burgess, K E·Published in Veterinary and comparative oncology·2017·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006-2013).
- Species:
- cat
Plain-English summary
A group of 32 cats diagnosed with intermediate to large cell gastrointestinal lymphoma (a type of cancer affecting the digestive system) were treated with a chemotherapy drug called lomustine. Half of the cats showed a positive response to the treatment, with some experiencing relief for up to 1450 days. The study found that factors like decreased appetite and anemia were linked to how long the cats remained stable after treatment. Overall, lomustine was found to be a well-tolerated and effective option for managing this type of lymphoma in cats.
People also search for: cat lymphoma treatment · lomustine for cats · feline cancer survival rates
Abstract
Multi-drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naïve feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown. This study evaluated the efficacy and tolerability of lomustine for the treatment of feline GI lymphoma. Thirty-two cats with histologically or cytologically confirmed intermediate/large cell GI lymphoma were evaluated retrospectively. Factors assessed included clinical signs, hematologic/biochemical parameters and use of l-asparaginase at induction. A response rate of 50% (16/32), with median duration of response of 302 days (range 64-1450 days), was found. Median progression-free interval was 132 days (range 31-1450 days), with overall median survival time of 108 days (range 4-1488 days). History of hyporexia, presence of anaemia and dose of lomustine were significantly associated with progression-free survival. Overall, lomustine is a well-tolerated and effective treatment for feline GI lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27277825/